Peter Attia: High HDL Cholesterol Doesn't Protect Your Heart. It Might Hurt It.

This post is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your health protocols.

Most people who track their health know the shorthand: LDL is bad cholesterol, HDL is good. The higher your HDL, the better your cardiovascular protection. It’s repeated in annual checkups, on nutrition labels, and in longevity protocols across the internet. Peter Attia’s latest deep-dive makes a direct case that this framing is wrong — and that very high HDL levels may indicate higher cardiovascular risk, not lower.

Why Everyone Believes This

The HDL-as-protective narrative has epidemiological roots. Population studies consistently found an inverse correlation between HDL-C levels and cardiovascular events: people with higher HDL tended to have fewer heart attacks. The simplest explanation — “HDL removes cholesterol from arteries” — was biologically plausible and easy to communicate. It became medical consensus without ever completing the step from correlation to causal mechanism.

HDL does play a role in reverse cholesterol transport, the process of shuttling cholesterol from peripheral tissues back to the liver. The problem is that HDL-C — the standard blood panel measure — captures cholesterol mass within HDL particles, not the functional capacity of those particles to actually perform reverse cholesterol transport. A high HDL-C number tells you there’s a lot of cholesterol inside HDL particles. It says almost nothing about whether those particles are doing their job.

What the Evidence Shows

The clinical trial evidence is unambiguous: every attempt to raise HDL-C pharmacologically has failed to reduce cardiovascular events.

Niacin trials (AIM-HIGH and HPS2-THRIVE) raised HDL-C significantly and produced no reduction in cardiovascular events. Fibrate trials showed similar results. CETP inhibitors — a class of drugs specifically designed to raise HDL-C — were tested in multiple large trials and either showed no benefit or, in one case (torcetrapib), increased cardiovascular mortality.

The SCARB1 gene variant is particularly instructive. SCARB1 encodes SR-BI, a receptor critical for HDL function in reverse cholesterol transport. People with a loss-of-function SCARB1 mutation have very high HDL-C — because their HDL particles aren’t clearing cholesterol efficiently. Those same people have higher cardiovascular disease risk than the population, not lower. The mechanism explains the paradox: dysfunctional HDL particles accumulate cholesterol rather than removing it, driving up the HDL-C number while worsening cardiovascular outcomes.

The mortality data adds a U-shaped curve: below roughly 40 mg/dL (in men) HDL-C is associated with higher risk; in the optimal range (50–80 mg/dL), risk is lowest; above 80 mg/dL, cardiovascular mortality risk begins climbing again. The conventional “higher is better” narrative doesn’t survive contact with the full dataset.

The Correction

HDL-C is a poor biomarker for cardiovascular protection. It measures particle cholesterol mass, not reverse cholesterol transport capacity, and pharmacologically raising it has never translated to clinical benefit. The corrected framing: HDL-C is one data point in a broader cardiovascular picture, not a protective factor in its own right.

More informative markers include:

• ApoA-I — the primary protein component of HDL particles, a better proxy for functional HDL particle count
• ApoB — the primary protein of LDL and VLDL particles; total ApoB tracks atherogenic particle burden more precisely than LDL-C
• Coronary artery calcium (CAC) score — direct measurement of plaque formation, independent of lipid panel values

Attia’s framing: if your HDL-C is 90+ mg/dL and you’re treating it as a longevity asset, you may be misreading a signal that warrants investigation rather than celebration.

Source: Peter Attia MD

Content created with AI assistance and reviewed for accuracy.